Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Marathon Digital Holdings Inc (MARA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance

Marathon Digital Holdings IncTrade
Vertex Pharmaceuticals IncorporatedTrade

Price performance (Past 24H)

Key statistics

Marathon Digital Holdings Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Marathon Digital Holdings Inc trades at $9.89 (market cap $3.69B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 36× Marathon Digital Holdings Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Marathon Digital Holdings Inc nearer its low. Which is the better fit depends on your goals.

MARAVRTX
Market Cap
$3.69B$132.79B
Sector
TechnologyHealth
52-Week High
$22.84$529.65
52-Week Low
$6.73$376.62
Enterprise Value
$5.74B$126.92B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Marathon Digital Holdings Inc

MARA Holdings trades at $10.09, down 5.26% amid a bearish technical signal and recent earnings misses. The stock faces fundamental pressure with a net income margin of -429.71% for 2026 and negative cash flow from operations. Despite this, analyst consensus remains optimistic with a $16.08 price target, and the company is pivoting its power infrastructure toward AI compute to complement Bitcoin mining.

The outlook is mixed; the high analyst buy rating and strategic pivot offer potential upside, but persistent losses, negative cash flow, and Bitcoin market volatility pose significant risks. Investor sentiment is cautious following Q2 2026 results, with the stock trading well below its 52-week high, highlighting both opportunity and substantial downside exposure.

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.

Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Marathon Digital Holdings Inc

Marathon Digital Holdings, Inc. is one of the largest publicly traded Bitcoin mining companies in North America. The company focuses on building and operating large-scale, cost-efficient Bitcoin mining facilities. Marathon's strategy centers on increasing its mining hash rate and using sustainable energy sources to expand its Bitcoin production. The company's performance is closely tied to the price of Bitcoin and the overall health of the digital asset mining industry.

Read more on MARA

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Read more on VRTX